<html lang="en">
<head>
<meta charset="utf-8"/>
<title offset="1769">Finasteride</title></head>
<body>
<h1>Finasteride</h1>
<hr/>

<p><strong>Finasteride</strong> (<a href="International_Nonproprietary_Name" title="wikilink">INN</a>, <a href="United_States_Adopted_Name" title="wikilink">USAN</a>, <a href="British_Approved_Name" title="wikilink">BAN</a>) (brand names <strong>Proscar</strong>, and <strong>Propecia</strong> by <a href="Merck_&amp;_Co" title="wikilink">Merck</a>, among other <a href="generic_drug" title="wikilink">generic names</a>; former developmental code name <strong>MK-906</strong>) is a <a class="uri" href="drug" title="wikilink">drug</a> used for the treatment of <a href="benign_prostatic_hyperplasia" title="wikilink">benign prostatic hyperplasia</a> (BPH) and <a href="male_pattern_baldness" title="wikilink">male pattern baldness</a> (MPB).<a class="footnoteRef" href="#fn1" id="fnref1"><sup>1</sup></a><a class="footnoteRef" href="#fn2" id="fnref2"><sup>2</sup></a> It is a <a href="SRD5A2" title="wikilink">type II</a> and <a href="SRD5A3" title="wikilink">type III</a> <a href="5α-reductase_inhibitor" title="wikilink">5α-reductase inhibitor</a>;<a class="footnoteRef" href="#fn3" id="fnref3"><sup>3</sup></a> 5α-reductase, an <a class="uri" href="enzyme" title="wikilink">enzyme</a>, converts <a class="uri" href="testosterone" title="wikilink">testosterone</a> to <a class="uri" href="dihydrotestosterone" title="wikilink">dihydrotestosterone</a> (DHT).<a class="footnoteRef" href="#fn4" id="fnref4"><sup>4</sup></a></p>
<h2 id="medical-uses">Medical uses</h2>
<h3 id="benign-prostatic-hyperplasia">Benign prostatic hyperplasia</h3>

<p>Physicians use finasteride for the treatment of BPH, informally known as an enlarged <a class="uri" href="prostate" title="wikilink">prostate</a>. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow. It provides less symptomatic relief than alpha-1 blockers such as <a class="uri" href="tamsulosin" title="wikilink">tamsulosin</a> and symptomatic relief is slower in onset (six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment). Symptomatic benefits are mainly seen in those with prostate volume &gt; 40 cm<sup>2</sup>. In long-term studies finasteride but not alpha-1 inhibitors reduce the risk of acute urinary retention (-57% at 4 years) and the need for surgery (-54% at 4 years). If the drug is discontinued, any therapeutic benefits reverse within about 6–8 months.<a class="footnoteRef" href="#fn5" id="fnref5"><sup>5</sup></a><a class="footnoteRef" href="#fn6" id="fnref6"><sup>6</sup></a><a class="footnoteRef" href="#fn7" id="fnref7"><sup>7</sup></a></p>
<h3 id="male-pattern-baldness">Male pattern baldness</h3>

<p>Finasteride is used to treat <a href="male_pattern_hair_loss" title="wikilink">male pattern hair loss</a> (androgenetic alopecia) in men only.<a class="footnoteRef" href="#fn8" id="fnref8"><sup>8</sup></a> Treatment provides about 30% improvement in hair loss after six months of treatment, and effectiveness only persists as long as the drug is taken.<a class="footnoteRef" href="#fn9" id="fnref9"><sup>9</sup></a></p>
<h3 id="off-label-uses">Off-label uses</h3>

<p>Finasteride is sometimes used in <a href="hormone_replacement_therapy" title="wikilink">hormone replacement therapy</a> for <a href="male-to-female_transsexual" title="wikilink">male-to-female transsexuals</a> in combination with a form of <a class="uri" href="estrogen" title="wikilink">estrogen</a> due to its <a class="uri" href="antiandrogen" title="wikilink">antiandrogen</a> properties. However, little <a href="clinical_trial" title="wikilink">clinical research</a> of finasteride use for this purpose has been conducted and evidence of efficacy is limited.<a class="footnoteRef" href="#fn10" id="fnref10"><sup>10</sup></a></p>
<h2 id="contraindications">Contraindications</h2>

<p>Finasteride is not approved for use in women, especially due to risks of <a href="birth_defects" title="wikilink">birth defects</a> in a <a class="uri" href="fetus" title="wikilink">fetus</a>. It is classified in the FDA <a href="pregnancy_category" title="wikilink">pregnancy category</a> X.<a class="footnoteRef" href="#fn11" id="fnref11"><sup>11</sup></a></p>
<h2 id="adverse-effects">Adverse effects</h2>

<p>Adverse effects from finasteride are rare.<a class="footnoteRef" href="#fn12" id="fnref12"><sup>12</sup></a> The FDA has added a warning to 5α-reductase inhibitors concerning an increased risk of high-grade <a href="prostate_cancer" title="wikilink">prostate cancer</a>, as the treatment of BPH lowers PSA, which could mask the development of prostate cancer.<a class="footnoteRef" href="#fn13" id="fnref13"><sup>13</sup></a><a class="footnoteRef" href="#fn14" id="fnref14"><sup>14</sup></a></p>

<p>Although overall incidence of male breast cancer in clinical trials for finasteride 5 mg was not increased, there are post-marketing reports of breast cancer in association with its use. Available evidence does not provide clarity as to whether there is a causative relationship between finasteride and these cancers.<a class="footnoteRef" href="#fn15" id="fnref15"><sup>15</sup></a><a class="footnoteRef" href="#fn16" id="fnref16"><sup>16</sup></a></p>

<p>The effect of finasteride on sexual function is controversial. There are <a href="case_reports" title="wikilink">case reports</a> of persistent diminished libido or erectile dysfunction after stopping the drug and the FDA has updated the label to inform healthcare professionals of these reports.<a class="footnoteRef" href="#fn17" id="fnref17"><sup>17</sup></a><a class="footnoteRef" href="#fn18" id="fnref18"><sup>18</sup></a> A 2010 review found moderate quality evidence that finasteride increased the risk of sexual dysfunction, but not of discontinuing treatment due to sexual side effects.<a class="footnoteRef" href="#fn19" id="fnref19"><sup>19</sup></a></p>

<p>A 2015 meta analysis found none of the clinical trials had adequate safety reporting and did not provide sufficient information to establish the safety profile for finasteride's treatment of hairloss. The study concluded the existing clinical trials of finasteride for hairloss provide very limited information on toxicity, are of poor quality, and seem to be systematically biased toward underdetection of adverse events. Moreover, the trials submitted to the FDA for approval for hairloss excluded most men who would normally be prescribed finasteride for androgenic alopecia.<a class="footnoteRef" href="#fn20" id="fnref20"><sup>20</sup></a><a class="footnoteRef" href="#fn21" id="fnref21"><sup>21</sup></a></p>

<p>When finasteride was originally approved for hair loss in 1997, the FDA approval review reported that it it appears well tolerated, with the most common side effects being related to sexual function.<a class="footnoteRef" href="#fn22" id="fnref22"><sup>22</sup></a> In many people these side effects resolve if the medication is stopped and occasionally resolve even if the medication is continued.<a class="footnoteRef" href="#fn23" id="fnref23"><sup>23</sup></a> They additionally state "the sexual functioning questionnaire seems to have given a sensitive reflection of the disturbance on sexual functioning".<a class="footnoteRef" href="#fn24" id="fnref24"><sup>24</sup></a></p>
<h2 id="mechanism-of-action">Mechanism of action</h2>

<p>Finasteride is a <a href="5α-reductase_inhibitor" title="wikilink">5α-reductase inhibitor</a>, specifically the <a href="SRD5A2" title="wikilink">type II</a> and <a href="SRD5A3" title="wikilink">III</a> <a href="isoenzyme" title="wikilink">isoenzymes</a>.<a class="footnoteRef" href="#fn25" id="fnref25"><sup>25</sup></a><a class="footnoteRef" href="#fn26" id="fnref26"><sup>26</sup></a> By inhibiting 5α-reductase, finasteride prevents conversion of testosterone to <a class="uri" href="dihydrotestosterone" title="wikilink">dihydrotestosterone</a> (DHT) by the type II and III isoenzymes, resulting in a decrease in serum DHT levels by about 65–70% and in prostate DHT levels by up to 85–90%,<a class="footnoteRef" href="#fn27" id="fnref27"><sup>27</sup></a><a class="footnoteRef" href="#fn28" id="fnref28"><sup>28</sup></a> where <a href="gene_expression" title="wikilink">expression</a> of the type II isoenzyme dominates. Unlike triple inhibitors of all three isoenzymes of 5α-reductase like <a class="uri" href="dutasteride" title="wikilink">dutasteride</a> which can reduce DHT levels in the entire body by more than 99%,<a class="footnoteRef" href="#fn29" id="fnref29"><sup>29</sup></a> finasteride does not completely suppress DHT production because it lacks significant inhibitory effects on the <a href="SRD5A1" title="wikilink">5α-reductase type I</a> isoenzyme, with 100-fold less affinity for I as compared to II.<a class="footnoteRef" href="#fn30" id="fnref30"><sup>30</sup></a> In addition to blocking the type II and III isoenzymes, finasteride competitively inhibits the 5β-reductase type II isoenzyme,<a class="footnoteRef" href="#fn31" id="fnref31"><sup>31</sup></a> though this is not believed to affect androgen metabolism.</p>

<p>By blocking DHT production, finasteride reduces androgen activity in the scalp. In the prostate, inhibition of 5α-reductase reduces prostate volume, which improves BPH and reduces risk of prostate cancer. Inhibition of 5α-reductase also reduces <a href="epididymis" title="wikilink">epididymal</a> weight, and decreases motility and normal morphology of spermatozoa in the epididymis.<a class="footnoteRef" href="#fn32" id="fnref32"><sup>32</sup></a></p>

<p>DHT helps activate the <a href="GABAA_receptor" title="wikilink">GABA<sub>A</sub> receptor</a>, which functions to tamp down signaling among neurons; because finasteride prevents the formation of DHT, it may contribute to a reduction of GABA<sub>A</sub> activity. Reduced GABA<sub>A</sub> has been implicated in depression, anxiety, and sexual dysfunction.<a class="footnoteRef" href="#fn33" id="fnref33"><sup>33</sup></a><a class="footnoteRef" href="#fn34" id="fnref34"><sup>34</sup></a><a class="footnoteRef" href="#fn35" id="fnref35"><sup>35</sup></a></p>
<h2 id="physical-and-chemical-properties">Physical and chemical properties</h2>

<p>Finasteride is a 4-azasteroid <a href="structural_analogue" title="wikilink">analogue</a> of testosterone and is <a class="uri" href="lipophilic" title="wikilink">lipophilic</a>.<a class="footnoteRef" href="#fn36" id="fnref36"><sup>36</sup></a></p>

<p>Drug trade names include Propecia and Proscar, the former marketed for male pattern baldness (MPB) and the latter for benign prostatic hyperplasia (BPH), both are products of <a href="Merck_&amp;_Co" title="wikilink">Merck &amp; Co</a>. There is 1 mg of finasteride in Propecia and 5 mg in Proscar. Merck's patent on finasteride for the treatment of BPH expired on June 19, 2006.<a class="footnoteRef" href="#fn37" id="fnref37"><sup>37</sup></a> Merck was awarded a separate patent for the use of finasteride to treat MPB. This patent expired in November 2013.<a class="footnoteRef" href="#fn38" id="fnref38"><sup>38</sup></a></p>
<h2 id="history">History</h2>

<p>In 1974, Julianne Imperato-McGinley of Cornell Medical College in New York attended a conference on birth defects. She reported on a group of <a class="uri" href="intersex" title="wikilink">intersex</a> children in the <a class="uri" href="Caribbean" title="wikilink">Caribbean</a> who appeared sexually <a href="Ambiguity" title="wikilink">ambiguous</a> at birth, and were initially raised as girls, but then grew external male genitalia and other masculine characteristic after onset of puberty. Her research group found these children shared a <a href="genetic_mutation" title="wikilink">genetic mutation</a>, causing <a href="5-alpha-reductase_deficiency" title="wikilink">deficiency of the 5α-reductase enzyme</a> and male hormone <a class="uri" href="dihydrotestosterone" title="wikilink">dihydrotestosterone</a> (DHT), which was found to have been the etiology behind abnormalities in male sexual development. Upon maturation, these individuals were observed to have smaller prostates which were underdeveloped, and were also observed to lack incidence of male pattern baldness.<a class="footnoteRef" href="#fn39" id="fnref39"><sup>39</sup></a><a class="footnoteRef" href="#fn40" id="fnref40"><sup>40</sup></a></p>

<p>In 1975, copies of Imperato-McGinley's presentation were seen by <a href="P._Roy_Vagelos" title="wikilink">P. Roy Vagelos</a>, who was then serving as Merck's basic-research chief. He was intrigued by the notion that decreased levels of DHT led to the development of smaller prostates. Dr. Vagelos then sought to create a drug which could mimic the condition found in these children to treat older men who were suffering from benign prostatic hyperplasia.<a class="footnoteRef" href="#fn41" id="fnref41"><sup>41</sup></a></p>

<p>In 1992, finasteride (5 mg) was approved by the <a href="Food_and_Drug_Administration_(United_States)" title="wikilink">U.S. Food and Drug Administration</a> (FDA) for treatment of BPH, which Merck marketed under the brand name Proscar.</p>

<p>In 1997, Merck was successful in obtaining FDA approval for a second indication of finasteride (1 mg) for treatment of MPB, which was marketed under the brand name Propecia.</p>
<h2 id="society-and-culture">Society and culture</h2>

<p>In 2005, the <a href="World_Anti-Doping_Agency" title="wikilink">World Anti-Doping Agency</a> banned finasteride because a laboratory in Germany discovered the drug could be used to mask <a href="anabolic_steroids" title="wikilink">steroid</a> abuse.<a class="footnoteRef" href="#fn42" id="fnref42"><sup>42</sup></a> It was removed from the list effective January 1, 2009, after improvements in testing methods made the ban unnecessary.<a class="footnoteRef" href="#fn43" id="fnref43"><sup>43</sup></a> Notable athletes who used finasteride for hair loss and were banned from international competition include <a href="Skeleton_(sport)" title="wikilink">skeleton racer</a> <a href="Zach_Lund" title="wikilink">Zach Lund</a>, <a href="Bobsleigh" title="wikilink">bobsledder</a> <a href="Sebastien_Gattuso" title="wikilink">Sebastien Gattuso</a>, <a href="Football_(soccer)" title="wikilink">footballer</a> <a class="uri" href="Romário" title="wikilink">Romário</a> and <a href="Goaltender" title="wikilink">ice hockey goaltender</a> <a href="José_Théodore" title="wikilink">José Théodore</a>.<a class="footnoteRef" href="#fn44" id="fnref44"><sup>44</sup></a><a class="footnoteRef" href="#fn45" id="fnref45"><sup>45</sup></a></p>

<p>In 2012, an <a href="advocacy_group" title="wikilink">advocacy group</a> called the Post-Finasteride Syndrome Foundation was formed; the group "coined the phrase 'post finasteride syndrome' which they say is characterised by sexual, neurological, hormonal and psychological side effects that can persist in men who have taken finasteride for hair loss or an enlarged prostate".<a class="footnoteRef" href="#fn46" id="fnref46"><sup>46</sup></a><a class="footnoteRef" href="#fn47" id="fnref47"><sup>47</sup></a></p>
<h2 id="research">Research</h2>

<p>Finasteride has been clinically tested for baldness in women; the results were no better than placebo.<a class="footnoteRef" href="#fn48" id="fnref48"><sup>48</sup></a></p>
<h2 id="see-also">See also</h2>
<ul>
<li><a class="uri" href="Alfatradiol" title="wikilink">Alfatradiol</a></li>
<li><a class="uri" href="Ketoconazole" title="wikilink">Ketoconazole</a></li>
<li><a class="uri" href="Minoxidil" title="wikilink">Minoxidil</a></li>
<li><a href="Saw_palmetto_extract" title="wikilink">Saw palmetto extract</a></li>
</ul>
<h2 id="references">References</h2>
<h2 id="external-links">External links</h2>
<ul>
<li><a href="http://www.proscar.com/">Proscar | Official website</a></li>
<li><a href="http://www.propecia.com">Propecia | Official website</a></li>
</ul>

<p>"</p>

<p><a href="Category:5-alpha-reductase_inhibitors" title="wikilink">Category:5-alpha-reductase inhibitors</a> <a class="uri" href="Category:Anxiogenics" title="wikilink">Category:Anxiogenics</a> <a class="uri" href="Category:Depressogenics" title="wikilink">Category:Depressogenics</a> <a class="uri" href="Category:Lactams" title="wikilink">Category:Lactams</a> <a class="uri" href="Category:Steroids" title="wikilink">Category:Steroids</a></p>
<section class="footnotes">
<hr/>
<ol>
<li id="fn1"><a href="#fnref1">↩</a></li>
<li id="fn2"><a href="#fnref2">↩</a></li>
<li id="fn3"><a href="#fnref3">↩</a></li>
<li id="fn4"></li>
<li id="fn5"><a href="#fnref5">↩</a></li>
<li id="fn6"><a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020180s037lbl.pdf">Proscar label</a><a href="#fnref6">↩</a></li>
<li id="fn7"><a href="#fnref7">↩</a></li>
<li id="fn8"><a href="#fnref8">↩</a></li>
<li id="fn9"><a href="#fnref9">↩</a></li>
<li id="fn10"><a href="#fnref10">↩</a></li>
<li id="fn11"></li>
<li id="fn12"></li>
<li id="fn13">FDA. Posted 9 June 2011. <a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258529.htm">5-alpha reductase inhibitors (5-ARIs): Label Change - Increased Risk of Prostate Cancer</a><a href="#fnref13">↩</a></li>
<li id="fn14"><a href="#fnref14">↩</a></li>
<li id="fn15"></li>
<li id="fn16">Medicines and Healthcare products Regulatory Agency Drug Safety Update. December 2009 <a href="http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087725">Finasteride: potential risk of male breast cancer</a><a href="#fnref16">↩</a></li>
<li id="fn17"></li>
<li id="fn18"><a href="#fnref18">↩</a></li>
<li id="fn19"><a href="#fnref19">↩</a></li>
<li id="fn20"><a href="#fnref20">↩</a></li>
<li id="fn21"><a href="#fnref21">↩</a></li>
<li id="fn22"></li>
<li id="fn23"></li>
<li id="fn24"><a href="#fnref24">↩</a></li>
<li id="fn25"></li>
<li id="fn26"><a href="#fnref26">↩</a></li>
<li id="fn27"></li>
<li id="fn28"><a href="#fnref28">↩</a></li>
<li id="fn29"></li>
<li id="fn30"></li>
<li id="fn31"><a href="#fnref31">↩</a></li>
<li id="fn32"><a href="#fnref32">↩</a></li>
<li id="fn33"><a href="#fnref33">↩</a></li>
<li id="fn34"><a href="#fnref34">↩</a></li>
<li id="fn35"><a href="#fnref35">↩</a></li>
<li id="fn36"><a href="#fnref36">↩</a></li>
<li id="fn37">[<a class="uri" href="http://www.rxsolutions.com/c/rxnews/rxnews_view.asp?Article=674&amp;type">http://www.rxsolutions.com/c/rxnews/rxnews_view.asp?Article=674&amp;type;</a>;=19 Primary Patent Expirations for Selected High Revenue Drugs]<a href="#fnref37">↩</a></li>
<li id="fn38">[<a class="uri" href="http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=020788∏_No=001&amp;table1">http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=020788∏_No=001&amp;table1;</a>;=OB_Rx fda.gov | Patent Expiration for Propecia]<a href="#fnref38">↩</a></li>
<li id="fn39"><a href="#fnref39">↩</a></li>
<li id="fn40">Emerick JE et al. for WebMD. Last Updated Updated: 29 May 2014 <a href="http://emedicine.medscape.com/article/924291-overview#showall">5-Alpha-Reductase Deficiency</a><a href="#fnref40">↩</a></li>
<li id="fn41"><a href="#fnref41">↩</a></li>
<li id="fn42"><a href="#fnref42">↩</a></li>
<li id="fn43">Staff, The Australian. 28 October 2008 <a href="http://www.theaustralian.com.au/archive/news/wada-removes-finasteride-from-ban-list/story-e6frg7mo-1111117876628?nk=0afe1009eb17d32f8f4d47ff9e091a08">WADA removes Finasteride from ban list</a><a href="#fnref43">↩</a></li>
<li id="fn44"></li>
<li id="fn45">Staff, Sydney Morning Herald. 9 October 2008 <a href="http://www.smh.com.au/zoom/archive/d229652">WADA takes Romario's drug off banned list</a><a href="#fnref45">↩</a></li>
<li id="fn46">Jill Margo for the <em>Australian Financial Review</em>. 26 Sept 2012 <a href="http://www.afr.com/p/lifestyle/mens_health/looking_at_care_with_critical_eye_ZRbAzUV4cRxZhspW7YRwBJ">Looking at care with a critical eye</a><a href="#fnref46">↩</a></li>
<li id="fn47"><a href="http://www.pfsfoundation.org/">Post-Finasteride Syndrome Foundation official website</a><a href="#fnref47">↩</a></li>
<li id="fn48"><a href="#fnref48">↩</a></li>
</ol>
</section>
</body>
</html>
